Chemistry:Izenivetmab
From HandWiki
Izenivetmab, sold under the brand name Lenivia, is a canine monoclonal antibody medication used for the alleviation of pain associated with osteoarthritis in dogs.[1]
Izenivetmab was authorized for veterinary use in Canada in October 2025,[2] and in the European Union in November 2025.[3]
Medical uses
Izenivetmab is indicated for the alleviation of pain associated with osteoarthritis in dogs.[4]
Society and culture
Legal status
Izenivetmab was authorized for veterinary use in Canada in October 2025,[2] and in the European Union in November 2025.[3]
Names
Izenivetmab is the international nonproprietary name.[5]
Izenivetmab is sold under the brand name Lenivia.[2][3]
References
- ↑ "Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 7-9 October 2025". 10 October 2025. https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-7-9-october-2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ 2.0 2.1 2.2 "Zoetis Announces Health Canada Approval of Lenivia (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 15 October 2025. Retrieved 22 December 2025.
- ↑ 3.0 3.1 3.2 "Zoetis Receives European Commission Marketing Authorization for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs" (Press release). Zoetis. 26 November 2025. Retrieved 22 December 2025.
- ↑ "Lenivia 0.5 mg". 20 November 2025. https://medicines.health.europa.eu/veterinary/en/600001881648.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information 36 (3). 2022.
External links
- "Izenivetmab ( Code - C188639 )". https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C188639.
 |  |
